An extremely rare case of synchronous occurrence in the larynx of intravascular lymphoma and in situ squamous cell carcinoma

Leuk Lymphoma. 2003 Jun;44(6):1053-7. doi: 10.1080/1042819031000063426.

Abstract

We present the first case of laryngeal intravascular lymphoma coexisting with in situ squamous cell carcinoma. The patient, a 53 years old man, presented with hoarseness starting a year ago and underwent laryngoscopy, which revealed two nodular lesions on his right vocal cord. The histological and immunohistochemical examination of the biopsy specimens established the diagnosis of in situ squamous cell carcinoma coexisting with intravascular lymphoma of T-cell origin. Taking in consideration all the available references, the larynx has not until now been reported as a primary site of involvement of intravascular (angiotropic) lymphomas, nor as a secondary location in the systematic course of this disease. Furthermore no cases have been reported in the literature, concerning the synchronous affection of the larynx by this lymphoma and in situ laryngeal carcinoma, or other type of neoplasm.

Publication types

  • Case Reports

MeSH terms

  • Antigens, CD / analysis
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biopsy
  • Carcinoma in Situ / complications
  • Carcinoma in Situ / drug therapy
  • Carcinoma in Situ / pathology*
  • Carcinoma, Squamous Cell / complications
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / pathology*
  • Cyclophosphamide / administration & dosage
  • Epirubicin / administration & dosage
  • Humans
  • Immunohistochemistry
  • Laryngeal Neoplasms / complications
  • Laryngeal Neoplasms / drug therapy
  • Laryngeal Neoplasms / pathology*
  • Lymphoma / complications
  • Lymphoma / drug therapy
  • Lymphoma / pathology*
  • Male
  • Middle Aged
  • Prednisone / administration & dosage
  • Time Factors
  • Treatment Outcome
  • Vascular Neoplasms / complications
  • Vascular Neoplasms / drug therapy
  • Vascular Neoplasms / pathology*
  • Vincristine / administration & dosage

Substances

  • Antigens, CD
  • Epirubicin
  • Vincristine
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CEOP protocol 1